Effect of varying nitric oxide release to prevent platelet consumption and preserve platelet function in an in vivo model of extracorporeal circulation

Skrzypchak, Amy M.; Lafayette, Nathan G.; Bartlett, Robert H.; Zhengrong Zhou; Frost, Megan C.; Meyerhoff, Mark E.; Reynolds, Melissa M.; Annich, Gail M.
May 2007
Perfusion;May2007, Vol. 22 Issue 3, p193
Academic Journal
The gold standard for anticoagulation during extracorporeal circulation (ECC) remains systemic heparinization and the concomitant risk of bleeding in an already critically ill patient could lead to death. Normal endothelium is a unique surface that prevents thrombosis by the release of antiplatelet and antithrombin agents. Nitric oxide (NO) is one of the most potent, reversible antiplatelet agents released from the endothelium. Nitric oxide released from within a polymer matrix has been proven effective for preventing platelet activation and adhesion onto extracorporeal circuits. However, the critical NO release (NO flux) threshold for thrombus prevention during ECC has not yet been determined. Using a 4-hour arteriovenous (AV) rabbit model of ECC, we sought to find this threshold value for ECC circuits, using an improved NO-releasing coating (Norel-b). Four groups of animals were tested at variable NO flux levels. Hourly blood samples were obtained for measurement of arterial blood gases, platelet counts, fibrinogen levels and platelet function (via aggregometry). A custom-built AV circuit was constructed with 36 cm of poly(vinyl)chloride (PVC) tubing, a 14 gauge (GA) angiocatheter for arterial access and a modified 10 French (Fr) thoracic catheter for venous access. The Norel-b coating reduced platelet activation and thrombus formation, and preserved platelet function - in all circuits that exhibited an NO flux of 13.65 10-10 mol·cm²·min-1. These results were significant when compared with the controls. With the Norel-b coating, the NO flux from the extracorporeal circuit surface can be precisely controlled by the composition of the polymer coating used, and such coatings are shown to prevent platelet consumption and thrombus formation while preserving platelet function in the animal.


Related Articles

  • The Physiology of Nitric Oxide: Control and Consequences. Fleming, Ingrid; Busse, Rudi // Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy A;Sep2004, Vol. 3 Issue 3, p189 

    Since its recognition as an endothelium-derived relaxing factor, the control and consequences of nitric oxide (NO) production has been investigated intensely. NO is not simply a vasodilator or regulator of smooth muscle tone but is a potent anti-platelet agent, neuromodulator and regulator of...

  • Alteration of Decreased Plasma NO Metabolites and Platelet NO Synthase Activity by Paroxetine in Depressed Patients. Chrapko, Wendy; Jurasz, Paul; Radomski, Marek W.; Archer, Stephen L.; Newman, Stephen C.; Baker, Glen; Lara, Nathalie; Le Mellédo, Jean-Michel // Neuropsychopharmacology;Jun2006, Vol. 31 Issue 6, p1286 

    Although major depression (MD) and cardiovascular disease (CVD) have been conclusively linked in the literature, the mechanism associating MD and CVD is yet undetermined. The purpose of this paper is to further investigate a potential mechanism involving nitric oxide (NO) and to examine the...

  • Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Aiello, Sistiana; Noris, Marina; Todeschini, Marta; Zappella, Sergio; Foglieni, Chiara; Benigni, Ariela; Corna, Daniela; Zoja, Carla; Cavallotti, Daniela; Remuzzi, Giuseppe // Kidney International;Jul1997, Vol. 52 Issue 1, p171 

    The article presents information on renal and systemic nitric oxide synthesis in rats with renal mass reduction. Nitric-oxide (NO), an L-arginine derivative, is implicated in neuronal transmission, immune response and vasodilation, beside acting as a platelet function modulator. The conversion...

  • Physiology and pathophysiology of nitric oxide. Ignarro, Louis J. // Kidney International;Jun1996 Supplement, Vol. 49, pS2 

    Nitric oxide (NO) was discovered to be a potent vasodilator, inhibitor of platelet aggregation, and active species of nitroglycerin before the discovery of endothelium- derived relaxing factor (EDRF) in 1980. Subsequent studies revealed that EDRF is NO, and is synthesized by mammalian cells from...

  • The Many Antithrombotic Actions of Nitric Oxide. Tziros, Constantine; Freedman, Jane E. // Current Drug Targets;Oct2006, Vol. 7 Issue 10, p1243 

    Vessel occlusion within a coronary artery is the precipitating event in unstable coronary syndromes and is primarily due to rupture of atheromatous plaque and subsequent thrombus formation. In the nondiseased vessel, the intact endothelium releases the vasodilator and antithrombotic agent nitric...

  • The Endothelium of Basilar Artery of Diabetic Rat Treated With Epoetin Delta. Loesch, Andrzej; Tang, Helen; Cotter, Mary A.; Cameron, Norman E. // Angiology;May2010, Vol. 61 Issue 4, p405 

    Erythropoiesis-stimulating agents (ESAs) are used to treat anemia associated with renal failure. It is now known that these agents also show a broad range of cell- and tissue-protective effects. In the current study, we explored whether an ESA, epoetin delta, affects vascular pathology linked to...

  • Oxygenator thrombosis: worst case after development of an abnormal pressure gradient - incidence and pathway. Wendel, H.P.; Philipp, A.; Weber, N.; Birnbaum, D.E.; Ziemer, G. // Perfusion;Jul2001, Vol. 16 Issue 4, p271 

    The development of an abnormally high pressure gradient (APG) before the membrane oxygenator (MO) is a complication that occurs during some extracorporeal circulation (ECC) procedures. The present study deals with the incidence of an APG and discusses a probable causative pathway by comparing...

  • The Endothelium and Platelets in Cardiovascular Disease: Potential Targets for Therapeutic Intervention. Tan, K. T.; Watson, S. P.; Lip, G. Y. H. // Current Medicinal Chemistry - Cardiovascular & Hematological Age;Jun2004, Vol. 2 Issue 2, p169 

    The interaction between platelets and endothelium has been implicated in many disease processes. It is now known that platelets may be involved in the initiation of atheroma, modulate various inflammatory responses, and contribute to endothelial dysfunction, in addition to their classical role...

  • Effects of Tadalafil on Platelets and Endothelium in Patients With Erectile Dysfunction and Cardiovascular Risk Factors: A Pilot Study. De Bon, Emiliano; Bonanni, Guglielmo; Saggiorato, Graziella; Bassi, PierFrancesco; Cella, Giuseppe // Angiology;Aug2010, Vol. 61 Issue 6, p602 

    Activation of endothelial cells and platelets is an initial step toward the development of cardiovascular disease. Erectile dysfunction (ED) may be an early manifestation of endotheliopathy. We evaluated the effects of tadalafil on cyclic nucleotides (cGMP and cAMP) and soluble adhesion...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics